|
http://cc.talkpoint.com/bcom001/102609a_...
Key Points... 1) LPATH has monopoly in bioactive lipids (i.e., ONLY LPATH has generated antibodies against bioactive lipids) 2) iSonep completed phase 1 for wet amd, well tolerated, no toxicity, (as we know from the published papers) Non-verlapping effects as well as overlapping effects with current treatment... Results of Phase 1: About to be presented... Sentiment : Strong Buy Rating :
 (No ratings) |
37 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.06